Our top pick for
Intellicheck Inc is a software-application business based in the US. Intellicheck shares (IDN) are listed on the NASDAQ and all prices are listed in US Dollars. Intellicheck employs 37 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$8.78|
|52-week range||$7.04 - $15.45|
|50-day moving average||$8.61|
|200-day moving average||$8.35|
|Wall St. target price||$13.13|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.03|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||0.92%|
|1 month (2021-09-21)||-0.23%|
|3 months (2021-07-21)||7.33%|
|6 months (2021-04-21)||7.20%|
|1 year (2020-10-21)||7.86%|
|2 years (2019-10-21)||66.29%|
|3 years (2018-10-19)||246.11%|
|5 years (2016-10-21)||448.75%|
|Revenue TTM||$13.4 million|
|Gross profit TTM||$9.3 million|
|Return on assets TTM||-3.27%|
|Return on equity TTM||-2.29%|
|Market capitalisation||$160.9 million|
TTM: trailing 12 months
There are currently 314,655 Intellicheck shares held short by investors – that's known as Intellicheck's "short interest". This figure is 30.2% down from 450,638 last month.
There are a few different ways that this level of interest in shorting Intellicheck shares can be evaluated.
Intellicheck's "short interest ratio" (SIR) is the quantity of Intellicheck shares currently shorted divided by the average quantity of Intellicheck shares traded daily (recently around 79861.675126904). Intellicheck's SIR currently stands at 3.94. In other words for every 100,000 Intellicheck shares traded daily on the market, roughly 3940 shares are currently held short.
However Intellicheck's short interest can also be evaluated against the total number of Intellicheck shares, or, against the total number of tradable Intellicheck shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intellicheck's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Intellicheck shares in existence, roughly 20 shares are currently held short) or 0.021% of the tradable shares (for every 100,000 tradable Intellicheck shares, roughly 21 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Intellicheck.
Find out more about how you can short Intellicheck stock.
We're not expecting Intellicheck to pay a dividend over the next 12 months.
Intellicheck's shares were split on a 1:8 basis on 12 August 2014. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Intellicheck shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Intellicheck shares which in turn could have impacted Intellicheck's share price.
Over the last 12 months, Intellicheck's shares have ranged in value from as little as $7.04 up to $15.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intellicheck's is 1.8487. This would suggest that Intellicheck's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Intellicheck, Inc. , a technology company, develops, integrates, and markets threat identification and identity authentication solutions for retail and bank fraud prevention, law enforcement threat identification, and mobile and handheld access control and security systems primarily in the United States. The company provides identity systems products, including commercial identification products, such as ID Check SDK for software developers; ID Check ? Retail, an identity authentication solution that authenticates identification documents; ID Check - Online that authenticates an on-line user's identification documents; ID Check - Mobile, which provides the fraud reduction benefits of an integrated identity validation system; ID Check ? IAM, a software application that speeds up check-in and ID verification within the property management systems; ID Check PC, a standalone software solution, which is designed to provide the features of ID Check for windows based platforms; Age ID, a smartphone or tablet-based solution for preventing sale of age-restricted products to minors; and Defense ID, a mobile and fixed infrastructure solution for threat identification, identity authentication, and access control to military bases, and other government and commercial facilities. It serves government, military, and commercial markets. The company was formerly known as Intellicheck Mobilisa, Inc. and changed its name to Intellicheck, Inc. in May 2017.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.